Thomas R. Alessi
Corporate Officer/Principal bei Intarcia Therapeutics, Inc.
Profil
Thomas R.
Alessi is currently the Vice President-Development & Manufacturing at Intarcia Therapeutics, Inc. He previously worked as the Director-Regulatory Affairs & Quality Assurance at Glycomed, Inc., Senior Director-Regulatory Affairs at Ansan Pharmaceuticals, Inc., Senior Scientist at Wyeth Ayersts Penicillin Business, and Senior Manager-Regulatory Affairs at Schering-Plough Research Institute.
Alessi received his graduate and doctorate degrees from the University of Rochester and his undergraduate degree from Allegheny College.
Aktive Positionen von Thomas R. Alessi
| Unternehmen | Position | Beginn |
|---|---|---|
Intarcia Therapeutics, Inc.
 Intarcia Therapeutics, Inc. BiotechnologyHealth Technology Intarcia Therapeutics, Inc. develops therapies for the treatment of chronic diseases. Its lead product candidate, ITCA 650, is currently in development for the treatment of type 2 diabetes. The firm’s platform technology is a proprietary subcutaneous delivery system that involves a matchstick-size, miniature osmotic pump implanted sub-dermally to provide continuous and consistent drug therapy, and the company’s proprietary formulation technology, which maintains stability of therapeutic proteins and peptides at human body temperatures for long extended periods of time. The company was founded by Mark Moran in June 1995 and is headquartered in Boston, MA. | Corporate Officer/Principal | 01.12.1997 |
Ehemalige bekannte Positionen von Thomas R. Alessi
| Unternehmen | Position | Ende |
|---|---|---|
Wyeth Ayersts Penicillin Business
 Wyeth Ayersts Penicillin Business Pharmaceuticals: OtherHealth Technology Part of Novartis AG, Wyeth Ayersts Penicillin Business is a Mexican company that produces penicillin. The company is located in Mexico. Wyeth Ayersts Penicillin Business was acquired by Novartis AG from Wyeth LLC on December 15, 1999. | Corporate Officer/Principal | - |
Glycomed, Inc.
 Glycomed, Inc. Pharmaceuticals: MajorHealth Technology Glycomed, Inc. discovers and developes pharmaceuticals based on complex carbohydrates. The company's drug discovery strategy utilizes medicinal chemistry to identify biologically active small molecules for therapeutic use. The company was founded by Brian G. Atwood in 1987 and is headquartered in San Diego, CA. | General Counsel | - |
Schering-Plough Research Institute
 Schering-Plough Research Institute Medical SpecialtiesHealth Technology Schering-Plough Research Institute provides pharmaceutical research. The company is headquartered in Kenilworth, NJ. | General Counsel | - |
| Ansan Pharmaceuticals, Inc. | General Counsel | - |
Ausbildung von Thomas R. Alessi
| Rochester Christian University | Doctorate Degree |
| Allegheny College | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 5 |
|---|---|
Glycomed, Inc.
Glycomed, Inc. Pharmaceuticals: MajorHealth Technology Glycomed, Inc. discovers and developes pharmaceuticals based on complex carbohydrates. The company's drug discovery strategy utilizes medicinal chemistry to identify biologically active small molecules for therapeutic use. The company was founded by Brian G. Atwood in 1987 and is headquartered in San Diego, CA. | Health Technology |
Wyeth Ayersts Penicillin Business
Wyeth Ayersts Penicillin Business Pharmaceuticals: OtherHealth Technology Part of Novartis AG, Wyeth Ayersts Penicillin Business is a Mexican company that produces penicillin. The company is located in Mexico. Wyeth Ayersts Penicillin Business was acquired by Novartis AG from Wyeth LLC on December 15, 1999. | Health Technology |
Intarcia Therapeutics, Inc.
Intarcia Therapeutics, Inc. BiotechnologyHealth Technology Intarcia Therapeutics, Inc. develops therapies for the treatment of chronic diseases. Its lead product candidate, ITCA 650, is currently in development for the treatment of type 2 diabetes. The firm’s platform technology is a proprietary subcutaneous delivery system that involves a matchstick-size, miniature osmotic pump implanted sub-dermally to provide continuous and consistent drug therapy, and the company’s proprietary formulation technology, which maintains stability of therapeutic proteins and peptides at human body temperatures for long extended periods of time. The company was founded by Mark Moran in June 1995 and is headquartered in Boston, MA. | Health Technology |
Schering-Plough Research Institute
Schering-Plough Research Institute Medical SpecialtiesHealth Technology Schering-Plough Research Institute provides pharmaceutical research. The company is headquartered in Kenilworth, NJ. | Health Technology |
| Ansan Pharmaceuticals, Inc. | Health Technology |
